Category: Press Release

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 2, 2012– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Tuesday, January 3, 2012 at 8:30 a.m. (ET). The call can be accessed by dialing 1-866-825-3354 (domestic) or 1-617-213-8063 (international) five minutes prior to the start of the call and providing the passcode 17542026. A

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 28, 2011– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference onTuesday, January 10, 2012 at 11:30 a.m. (PST) at the Westin St. Francis Hotel in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of

Download PDF The Trial, BATON-CRC, is Second in Series of Tivozanib Biomarker Trials CAMBRIDGE, MASS.–(BUSINESS WIRE)–Dec. 22, 2011– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination with modified FOLFOX6 (mFOLFOX6) compared to bevacizumab in combination with mFOLFOX6 as

Download PDF CAMBRIDGE, Mass. & INGELHEIM, Germany–(BUSINESS WIRE)–Dec. 1, 2011– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO’s novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer (NSCLC). Boehringer Ingelheim

Download PDF Tivozanib Highlighted at EMUC 2011; New Data Featured at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference CAMBRIDGE, Mass., Nov 03, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported clinical data evaluating its lead product candidate tivozanib will be featured at the 3rd European Multidisciplinary Meeting on Urological Cancers

Download PDF CAMBRIDGE, Mass., Oct 26, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company’s third quarter ended September 30, 2011 will be released before the market opens on Wednesday, November 2, 2011. The AVEO management team will host a conference call discussing the company’s financial results

Download PDF CAMBRIDGE, Mass., Aug 31, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the company’s management will present a company overview at upcoming investment conferences. David Johnston, chief financial officer, is scheduled to present at the William Blair 2011 Life Sciences Conference on Wednesday, September 7, 2011 at 2:00 p.m.

Download PDF CAMBRIDGE, Mass., Aug 02, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Canaccord Genuity 31st Annual Growth Conference on Tuesday, August 9, 2011 at 8:30 a.m. (EDT) in Boston. A live webcast of AVEO’s presentation can be

Download PDF CAMBRIDGE, Mass., Jul 28, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reviewed key second quarter accomplishments and reported consolidated financial results for the second quarter of 2011. “We are very pleased with the progress we have made against our corporate goals for 2011 in the first half of the year,

Download PDF CAMBRIDGE, Mass., Jul 21, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that financial results for the company’s second quarter ended June 30, 2011 will be released before the market opens on Thursday, July 28, 2011. The AVEO management team will host a conference call discussing the company’s financial results